Cargando…
CD34 (+) cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina
Patients with refractory angina who are suboptimal candidates for further revascularization have improved exercise time, decreased angina frequency, and reduced major adverse cardiac events with intramyocardial delivery of CD34(+) cells. However, the effect of CD34(+) cell therapy on health care exp...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519768/ https://www.ncbi.nlm.nih.gov/pubmed/32531108 http://dx.doi.org/10.1002/sctm.20-0046 |